Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GHRS |
---|---|---|
09:32 ET | 272 | 8.25 |
09:34 ET | 2400 | 8.5337 |
09:56 ET | 600 | 8.04 |
10:10 ET | 2839 | 8.04 |
10:17 ET | 100 | 7.94 |
10:28 ET | 100 | 7.96 |
10:32 ET | 300 | 7.95 |
10:44 ET | 400 | 8.32 |
10:46 ET | 130 | 8.255 |
10:48 ET | 200 | 8.2 |
11:15 ET | 100 | 8.26 |
11:24 ET | 425 | 8.09 |
11:49 ET | 700 | 8.05 |
11:51 ET | 500 | 8.04 |
11:54 ET | 100 | 8.15 |
12:09 ET | 100 | 8.12 |
12:12 ET | 200 | 8.07 |
12:30 ET | 220 | 8.4271 |
12:38 ET | 510 | 8.085 |
01:06 ET | 401 | 8.08 |
01:15 ET | 200 | 8.018 |
01:21 ET | 200 | 7.99 |
01:26 ET | 4926 | 7.96 |
01:33 ET | 4801 | 7.94 |
02:00 ET | 192 | 8.01 |
02:08 ET | 100 | 8.015 |
02:27 ET | 418 | 8.03 |
02:42 ET | 100 | 8.035 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
GH Research PLC | 431.8M | 0.0x | --- |
Anavex Life Sciences Corp | 450.3M | -11.0x | --- |
Larimar Therapeutics Inc | 459.4M | -5.9x | --- |
Nkarta Inc | 402.9M | -2.8x | --- |
ACELYRIN Inc | 465.4M | -1.4x | --- |
Northwest Biotherapeutics Inc | 409.6M | -4.9x | --- |
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $431.8M |
---|---|
Revenue (TTM) | --- |
Shares Outstanding | 52.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | --- |
Book Value | $4.21 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.